Shivam Singh

Mr. Shivam Singh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
SASouvik Adak
Souvik Adak
Shivam SinghShivam Singh
Shivam Singh
RJRidhi Jain
Ridhi Jain
ATAbhilasha Tiwari
Abhilasha Tiwari
BSBinny Singh
Binny Singh
RSRajesh Kumar Sharma
Rajesh Kumar Sharma
Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative condition that worsens with time and causes memory loss and cognitive impairment. For prompt intervention and management of AD, early detection is essential. Screening models play a crucial role in identifying individuals at risk of developing AD before the onset of noticeable clinical symptoms. This review summarizes a wide range of in vitro and in vivo screening models currently utilized in AD research, highlighting their advantages and limitations. In vitro systems-such as cell lines and primary neuronal cultures-provide controlled settings to investigate cellular mechanisms and drug efficacy. In contrast, in vivo models, including transgenic rodents and other animals, better replicate the complex biological features of AD. Each model type comes with distinct benefits and limitations concerning clinical relevance, cost-effectiveness, and ethical challenges. By evaluating the utility and constrains of these models, this article seeks to assist researchers in choosing suitable platforms for preclinical investigations and support the advancement of improved diagnostic tools and therapeutic strategies for AD.

28 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Shivam SinghShivam Singh
Shivam Singh
SKSunita Kularia
Sunita Kularia
SSShivakshi Shukla
Shivakshi Shukla
MSMithilesh Singh
Mithilesh Singh
MKManish Kumar
Manish Kumar
ASAshish Kumar Sharma
Ashish Kumar Sharma
Asthma is a chronic inflammatory respiratory condition characterised by airway constriction, smooth muscle spasm, and severe morbidity. It affects around 300 million people globally, with children being especially vulnerable. Despite its worldwide effect, the invention of innovative asthma medicines has been slow over the last 5 decades, leaving significant unmet requirements in asthma care. Although intriguing medicines have demonstrated efficacy in animal models, many fail to fulfil safety and effectiveness requirements in human trials, highlighting the critical need for more predictive models that better transfer to human results. This comprehensive review investigates the mechanisms and efficacy of anti-asthmatic drugs using both genetic and conventional animal models. Both genetic and traditional models of anti-asthmatic agents, their characteristics, and their significance are summarized as: In-vitro Models: Histamine receptor assay, Cell Culture Method, WST Assay, Spasmolytic Activity of the Lungs of Guinea Pigs, Airway and Vascular Responses to an Isolated Lung, The Isolated Perfused Guinea Pig Trachea’s Reactivity. In-Vivo Models: In vivo small animal models, Broncho Spasmolytic Activity in anaesthetized Guinea Pigs, Guinea Pigs Respiratory and Vascular Dysfunction Caused by Arachidonic Acid or platelet-activated factor (PAF), Guinea Pig Asphyxia Induced by Serotonin Aerosol and Anaphylactic Microshock, Guinea Pigs Under Anaesthesia: Histamine-Induced Bronchoconstriction, Microshock in Rabbits and Pneumotachography in Guinea Pigs, Guinea Pig Bronchial Hyperactivity, Guinea Pig Airway Microvascular Leakage, Mice With Inflammatory Airways. Conclusion: This review focusses on the benefits and limitations of current animal models in asthma research, emphasising the need for more sophisticated, predictive models to decrease translational failures. By critically evaluating these models, the review emphasises their importance in directing anti-asthmatic drug development and highlights the urgent need for innovation to bridge the gap between preclinical success and clinical efficacy.

6 December 2025 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
Shivam SinghShivam Singh
Shivam Singh
ASAshish Kumar Sharma
Ashish Kumar Sharma
A newly identified autoinflammatory condition called CANDLE syndrome (chronic atypical neutrophilic dermatosis with lipodystrophy and increased temperature) is characterized by early onset, recurring fever, skin lesions, and multisystemic inflammatory symptoms. It has been demonstrated that the majority of patients had PSMB8 gene mutations. It leads to dysfunction in the proteasome/immunoproteasome system and subsequent overproduction of type 1 interferons. Patients usually exhibit lipodystrophy, fever, rashes on the skin, and malnutrition in the early stages of infancy. The results of skin biopsies, laboratory tests, and clinical symptoms all support the diagnosis of CANDLE syndrome. Although there isn't a specific treatment for CANDLE syndrome, JAK inhibitors like baricitinib have demonstrated some effectiveness in treating its symptoms. For CANDLE syndrome patients to receive the right therapeutic interventions, early diagnosis and molecular testing are essential. A positive interferon signature has also been found to be a diagnostic indicator for the condition. Although there are no particular treatments for CANDLE syndrome, research is still being done to determine how well immunosuppressive medications, biological agents, and glucocorticoids work in treating the condition. Current research generally aims to improve the quality of life for individuals with CANDLE syndrome through the development of targeted medications, the elucidation of genetic determinants, and the advancement of diagnostic methods.

11 May 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RYRishikesh Yadav
Rishikesh Yadav
Shivam SinghShivam Singh
Shivam Singh
SKSandeep Kumar
Sandeep Kumar
AKArindam Kolay
Arindam Kolay
Dr. Himanshu SharmaDr. Himanshu Sharma
Dr. Himanshu Sharma
MYMeena K. Yadav
Meena K. Yadav
Cancer is one of the leading causes of morbidity and mortality worldwide, accounting for a considerable global health burden and approximately 10 million deaths every year. There have been monumental breakthroughs in cancer research; but translating promising preclinical data into successful evolving drug therapies continues to have an enormous challenge. This challenge is further emphasised by the very high rate of attrition throughout clinical development, confirming the inadequacies of existing predictive screening platforms and emphasising the need for more predictive preclinical models. Therefore, this paper provides an overview of the various major types of preclinical models used to evaluate anticancer drugs, along with their respective strengths, weaknesses, and translational relevance. Classical in vitro cytotoxicity screens provide an essential element to early phase high-throughput cytotoxicity evaluations. More sophisticated 3D and 4D in vitro tumour models, patient-derived organoids, and organ-on-chip technologies allow for improved modelling of tumour structure and architecture, microenvironmental complexity, and drug penetration dynamics, improving accuracy in predicting in vivo activity of agents being screened in vitro . Further, in vivo model systems, provide essential in vivo data to dissect and understand the biology of tumours, pharmacokinetics, toxicity, and therapeutic efficacy of agents used to treat cancer. Rational drug discovery will be further enhanced through increasingly available emerging technologies such as bioinformatics, molecular docking, genomics and omics-based methods. Although traditional animal and cell line models are needed in drug discovery; the shortcomings of these systems, in their inability to reproduce the full complexity of human tumours means they account for a large proportion of translational failures. This comprehensive review shows how developing multi-faceted, human-comparable and technologically sophisticated screening platforms for test drugs will increase predictivity, speed up drug development for cancer treatment and improve clinical benefit from tested drugs.

28 January 2023 in Health Sciences Review
Verified
Journal Article
Open access
MBMehvish Bhat
Mehvish Bhat
MZMohammad Zaid
Mohammad Zaid
Shivam SinghShivam Singh
Shivam Singh
KGKartik Gill
Kartik Gill
JTJunaid Ishaq Tantray
Junaid Ishaq Tantray
ASAshish Kumar Sharma
Ashish Kumar Sharma

17 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
JTJunaid Tantray
Junaid Tantray
ASAshish Kumar Sharma
Ashish Kumar Sharma
Shivam SinghShivam Singh
Shivam Singh
MZMohammad Zaid
Mohammad Zaid
MBMehvish Bhat
Mehvish Bhat
RSRavindra Pal Singh
Ravindra Pal Singh
Objectives: This study was to investigate cardioprotective effects of ranolazine and to explore possible secondary mechanisms beyond the cellular studies have demonstrated inhibition of late sodium channel(INaL) leads to reduction in calcium load during cardiac ischemia. We hypothesized that ranolazine-induce Nitric oxide, Adenosine, Bradykinin and K+ATPase like ischemic preconditioning. Methods: Ischemia-reperfusion injury was established using Langendroff’s technique. 20minute ischemia and 40minute reperfusion to coronary artery to isolated heart was model of myocardial infarction. There were following groups: Control(Ischeamia-Reperfusion), Ischemic preconditioning, ranolazine(100µmol/L), ranolazine+L-NAME(30µmol/L) and ranolazine+Aminoguanidine(30µmol/L), ranolazine+Theophylline(50µmol/L), ranolazine+Aminophylline(50µmol/L), ranolazine+Enalapiril(100µmol/L), ranolazine+Losartan(50µmol/L), ranolazine+5-hydroxydecanoate(30µmol/L), ranolazine+glimepiride(50µmol/L) in perfusate. Results: Ranolazine found cardioprotection(Infarct Size:5.334± 0.422 v/s control 65.667±0.558; LDH:101.500±1.147U/L v/s control 155.500±0.957U/L; CK-MB: 100.167±1.302U/L v/s control 198.500±1.803U/L) Ischemic Preconditioning found cardioprotection(Infarct Size:5.1667±0.478 v/s control 65.667±0.558; LDH:101.667±2.789U/L v/s control 155.500±0.958U/L; CK-MB: 97.167±1.721U/L v/s control 198.500±1.803U/L) Ranolazine+L-NAME(Infarct Size:64.167±0.872 v/s control ranolazine 5.334± 0.422; LDH: 154.667±1.256U/L v/s control ranolazine 101.500±1.147; CK-MB:200.167±1.537U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Aminoguanidine(Infarct Size: 64.500±0.885 v/s control ranolazine 5.334± 0.422; LDH: 154.833±1.1377U/L v/s control ranolazine 101.500±1.147U/L; CK-MB:198.333±1.145U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Theophylline (Infarct Size: 64.667±0.760 v/s control ranolazine 5.334± 0.422; LDH: 155.167±1.301U/L v/s control ranolazine 101.500±1.147; CK-MB:199.167±1.376U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Aminophylline (Infarct Size: 65.167±0.601 v/s control ranolazine 5.334± 0.422; LDH: 155.333±0.615U/L v/s control ranolazine 101.500±1.147U/L; CK-MB: 199.500± 1.765U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Enalapiril (Infarct Size: 64.667±0.615 v/s control ranolazine 5.334± 0.422; LDH: 154.667± 1.085U/L v/s control ranolazine 101.500±1.147; CK-MB: 201.8333±1.990U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Losartan (Infarct Size: 63.667±1.282 v/s control ranolazine 5.334± 0.422; LDH: 155.167± 0.909U/L v/s control ranolazine 101.500±1.147U/L; CK-MB: 199.500±2.349U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+5-hydroxydecanoate (Infarct Size: 63.833±1.352 v/s control ranolazine 5.334± 0.422; LDH: 154.667±1.054U/L v/s control ranolazine 101.500±1.147; CK-MB: 201.833±1.815U/L v/s control ranolizine 100.167±1.302U/L) Ranolazine+Glimepiride (Infarct Size: 63.667±0.989 v/s control ranolazine 5.334± 0.422; LDH: 155.833±1.352U/L v/s control ranolazine 101.500±1.147U/L; CK-MB: 199.833±1.579U/L v/s control ranolizine 100.167±1.302U/L) Conclusions: As per confirmation Ranolazine and ischemic preconditioning have brought cardioprotection as reduced Infract Size, LDH & CK-MB. Wereas, treatment of L-NAME, Aminoguanidine, Theoplylline, Aminoplylline, Enalapiril, Losartan, 5-hydroxydecanoate & Glimepiride increased infract size, LDH & CK-MB. Hence it is proved that ranolazine involves Nitric oxide, Adenosine, Bradykinin and K+ATPase as secondary messenger in cardioprotection like ischemic preconditioning.